AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First US Multiple Sclerosis Patient Dosed with IMS001

AgeX Therapeutics, Inc. announced that ImStem Biotechnology, Inc., a biopharmaceutical company developing human ESC-derived mesenchymal stem cells, has dosed the first US multiple sclerosis patient with ImStem’s lead investigational drug candidate IMS001.